Association between screening for osteoporosis and the incidence of hip fracture

Annals of Internal Medicine

Volumn 142, Issue 3, 2005, Pages 173-181

  Kern, Lisa M ^a   Powe, Neil R ^b   Levine, Michael A ^b   Fitzpatrick, Annette L ^b   Harris, Tamara B ^b   Robbins, John ^b   Fried, Linda P ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGE DETERMINATION; AGED; ANAMNESIS; ARTICLE; BONE DENSITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENDER; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; OSTEOPOROSIS; OUTCOMES RESEARCH; POPULATION RESEARCH; PRIORITY JOURNAL; RACE; RISK FACTOR; SCREENING; UNITED STATES;

EID: 13244276390     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-142-3-200502010-00007     Document Type: Article

References (42)

1. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341:72-5.
2. Stevens JA, Olson S. Reducing falls and resulting hip fractures among older women. In: Centers for Disease Control and Prevention. CDC Recommendations Regarding Selected Conditions Affecting Women's Health. MMWR Recomm Rep. 2000;49(RR-2):1-12. Accessed at www.cdc.gov/mmwr/pdf/rr /rr4902.pdf on 4 December 2004.
3. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761-7.
4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
5. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, et al. Prevention of nonvertebral fractutes by alendronate. A meta-analysis. Alendronate Osteopotosis Tteatment Study Groups. JAMA. 1997;277:1159-64.
6. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendtonate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41.
7. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebtal fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82.
8. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebtal and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-52.
9. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-40.
10. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-95.
11. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003.
12. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526-8.
13. Nelson HD, Helrand M, Woolf SH, Allan JD. Screening for postmenopausal osteopotosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:529-41.
14. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263-76.
15. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:358-66.
16. University of California CHS Bone Density Coordinating Centet and Osteoporosis Research Group. Cardiovascular Health Study: DXA Quality Assurance Manual fot Hologic QDR-2000 Bone Densitometers. San Francisco: University of California; 1994.
17. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767-73.
18. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86:32-8.
19. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA. 2001;285:1850-5.
20. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000;283:3211-6.
21. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48:314-8.
22. McPhillips JB, Pellettera KM, Barrett-Connor E, Wingard DL, Criqui MH. Exercise patterns in a population of older adults. Am J Prev Med. 1989;5:65-72.
23. Taylor HL, Jacobs DR Jr, Schucker B, Knudsen J, Leon AS, Debacker G. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis. 1978;31:741-55.
24. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-56.
25. King G, Honaker J, Joseph A, Scheve K. Analyzing incomplete political science data: an alternative algorithm for multiple imputation. American Political Science Review. 2001;95:49-69.
26. Honaker J, Joseph A, King G, Scheve K, Singh N. Amelia: A Program for Missing Data. Windows version 2.1. Cambridge, MA: Harvard Univ; 2001.
27. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores [Editorial]. Ann Intern Med. 2002;137:693-5.
28. Rosenbaum PR. Propensity score. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. vol 5 (Pri-Sph). New York: Wiley; 1998:3551-5.
29. Carlin JB, Li N, Greenwood P, Coffey C. Tools for analyzing multiple imputed datasets. The Stata Journal. 2003;3:226-44.
30. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-81.
31. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics. 1998;54:948-63.
32. Guyatt GH, Cranney A, Griffith L, Walter S, Krolicki N, Favus M, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am. 2002;31:659-79, xii.
33. Guo Z, Wills P, Viitanen M, Fastbom J, Winblad B. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study. Am J Epidemiol. 1998;148:887-92.
34. Felson DT, Kiel DP, Anderson JJ, Kannel WB. Alcohol consumption and hip fractures: the Framingham Study. Am J Epidemiol. 1988;128:1102-10.
35. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477-501.
36. Rodríguez-Martínez MA, Garcia-Cohen EC. Role of Ca(2+) and vitamin D in the prevention and treatment of osteoporosis. Pharmacol Ther. 2002;93:37-49.
37. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-6.
38. Center for Drug Evaluation and Research, Food and Drug Administration. Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed at www.fda.gov/cder/ob/default.htm on 2 November 2004.
39. Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE, Cumming RG, Rowe BH. Interventions for preventing falls in elderly people (Cochrane Review). In: The Cochtane Library, Issue 3, 2002. Chichester, UK: Wiley; 2002.
40. Horwitz RI, Viscoli CM, Clemens JD, Sadock RT. Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med. 1990;89:630-8.
41. Medicare Preventive Services: Osteoporosis, Diabetes and Prostate Cancer. Washington, DC: Centers for Medicare & Medicaid Services; 2004. Accessed at www.cms.hhs.gov/medleain/ost_dia_procan04.pdf on 2 November 2004.
42. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35.